Home›Lutetium Lu 177 Dotatate›Lutetium Lu 177 Dotatate + Octreotide

Does Lutetium Lu 177 Dotatate Interact with Octreotide?

Lutetium Lu 177 Dotatate and Octreotide have a major drug interaction according to U.S. FDA drug labeling data. Short-acting octreotide competitively binds to somatostatin receptors and may interfere with LUTATHERA efficacy. Discontinue at least 24 hours prior to each LUTATHERA dose. The mechanism involves competitive binding to somatostatin receptors. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.

Severity
Major
Octreotide Class
Somatostatin Analog
Management
Close medical supervision required
Data Source
U.S. FDA via OpenFDA

How This Interaction Works

The interaction between Lutetium Lu 177 Dotatate and Octreotide occurs because competitive binding to somatostatin receptors. Clinically, this means short-acting octreotide competitively binds to somatostatin receptors and may interfere with lutathera efficacy. discontinue at least 24 hours prior to each lutathera dose. This is classified as a major interaction, meaning it could cause serious harm if not properly managed. Your healthcare provider may need to adjust dosages, substitute one medication, or increase monitoring frequency.

What To Tell Your Doctor or Pharmacist

If you are taking Lutetium Lu 177 Dotatate and your doctor is considering prescribing Octreotide (or vice versa), make sure to:

  • Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
  • Ask whether the benefits of combining these medications outweigh the risks for your specific situation
  • Ask what symptoms to watch for that would indicate the interaction is causing problems
  • Ask how frequently you should be monitored while these are co-prescribed
  • Ask whether any dosage adjustments are needed
  • Never stop or change either medication without first consulting your healthcare provider
💊 Lutetium Lu 177 Dotatate(Lutathera)+💊 Octreotide(Mycapssa)

Severity & Interaction Details

⚠️
major
Use with caution — major interaction
Serious risk of clinically significant harm. Generally avoid; if used, monitor closely.
Severity scale
MinorContra
On record
Yes
Drug A class
—
Drug B class
Somatostatin Analog
Source
NLP:lutetium lu 177 dotatate

What this means in plain English

Short-acting octreotide competitively binds to somatostatin receptors and may interfere with LUTATHERA efficacy. Discontinue at least 24 hours prior to each LUTATHERA dose.

What the FDA label says

"Competitive binding to somatostatin receptors"

📖 Source: NLP:lutetium lu 177 dotatate

Share this result:XFacebookWhatsAppReddit
Add more drugs
Check Lutetium Lu 177 Dotatate and Octreotide against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.